US govt seeks new trial in Gilead HIV drug patent case
The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.
FTC sues to bar Amgen from major IP $28bn acquisition
The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.
Teva loses plea against GSK’s $235m ‘skinny label’ win
The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
LabCorp hit with further $100m in DNA test patent case
Judge Albright awards punitive damages due to the 'intentional' nature of the infringement | Ravgen fails to secure a three-fold increase on damages awarded by a US jury last year.
Teva and Apotex prevail in sleep drug dispute
The dispute centred on a treatment that helps people adjust their circadian rhythm | Path now clear for generic drug makers to unveil biosimilar versions of the drug.
Gilead defeats US govt in billion-dollar HIV drug patent suit
Jury finds three US government patents over PrEP to be invalid | Case thought to be the first time US government has sued a pharmaceutical firm over patents.
BMS loses UK appeal over blood-thinning drug
Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.
AWA promotes female patent attorney to group CEO
The new CEO is currently Denmark CEO and group VP for the firm, who has ‘spearheaded international growth efforts’.
Amgen sues generic drug maker over bone treatments
Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.
Vizgen accuses Harvard and 10x of patent licence cover-up
Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
